John D. Rodwell
Princeton University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John D. Rodwell.
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology | 1986
Vernon L. Alvarez; Mei-Li Wen; Chyi Lee; A.Dwight Lopes; John D. Rodwell; Thomas J. McKearn
Site-specific modification of monoclonal antibodies at their oligosaccharide had previously been demonstrated to produce excellent 111In imaging in a xenograft model using a Brown Norway (BN) rat lymphoma and a rat anti-BN MHC monoclonal antibody [Lee C. et al. Fed. Proc. Abstr. 43 3014 (1984)]. These results are due, in part, to lack of liver uptake, so we wanted to evaluate the extent of hepatic uptake observed with different monoclonal antibodies in normal mice. Biodistribution data were obtained for four monoclonal antibodies by first modifying each antibody at its carbohydrate with a diethylenetriaminepentaacetic acid (DTPA) derivative. The antibodies were then labelled with 111In and injected into normal mice. Images were obtained 24 h post-injection, and at 48 h the mice were dissected and the tissue-to-blood (T:B) ratios determined. T:B ratios were approximately 1 (or less) for every organ evaluated, indicating minimal non-specific uptake into these organs. Data is also presented for the BN-rat system which shows excellent localization into the tumor xenograft and low non-specific organ uptake. These data indicate that modification of antibodies site-specifically at their oligosaccharide results in minimal non-specific uptake into non-target tissues and enhanced localization into the tumor target, and that this may represent a preferred method for production of 111In labelled antibodies.
Vaccine | 1996
Fabrice Geoffroy; Nicolas Moachon; John D. Rodwell; Gerard Quash
Sodium periodate (10 mM, 4 degrees C) inactivated murine cytomegalovirus (MCMV) very rapidly (loss of 2 to 3 log of viral infectivity per minute). Periodate-treated MCMV (PI-MCMV) was shown to be innocuous in mice, as determined by the inability of the virus to replicate. PI-MCMV induced a strong humoral immune response, with a high level of neutralizing antibodies. Mice immunized with PI-MCMV were protected against death and infection, when a lethal challenge with the virulent virus was administered 3 weeks after immunization and from death but not infection when virulent virus was administered at 3 months. Finally, no reactivation of potentially latent challenge virus (sublethal dose at 3 weeks) was observed in animals immunosuppressed at 6 months after immunization. Taken together, these results suggest that periodate could serve as an inactivating agent to prepare killed vaccines.
Archive | 1982
John D. Rodwell; Thomas J. McKearn
Archive | 1984
Vernon L. Alvarez; John D. Rodwell; Chyi Lee; John W. F. Goers; Richard Charles Siegel; Thomas J. McKearn
Archive | 1984
John W. F. Goers; Hurley Dalton King; Chyi Lee; Daniel J. Coughlin; Vernon L. Alvarez; John D. Rodwell; Thomas J. McKearn
Archive | 1991
John D. Rodwell; Thomas J. McKearn; Vernon L. Alvarez; Robert David Radcliffe
Archive | 1989
John W. F. Goers; Hurley Dalton King; Chyi Lee; Daniel J. Coughlin; Vernon L. Alvarez; John D. Rodwell; Thomas J. McKearn
Archive | 1989
Daniel J. Coughlin; John D. Rodwell
Archive | 1988
H. Dalton King; Anthony Dwight Lopes; Robert David Radcliffe; John D. Rodwell; Daniel J. Coughlin
The Journal of Nuclear Medicine | 1994
Linda C. Knight; Robert David Radcliffe; Alan H. Maurer; John D. Rodwell; Vernon L. Alvarez